marked.bio

Company

Chia Tai Tianqing (Sino Biopharm)

7 active trials that select patients by a biomarker on marked.bio, across 3 biomarkers; 4 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

garsorasib 1afatinib 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

7 of 17 trials shown

  1. D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

    Recruiting Phase 3 Chia Tai Tianqing (Sino Biopharm) Started 2024Primary completion 2026-10 NCT06300177

    garsorasibdocetaxel

    D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior S…

    KRAS G12CStatus may be outdated, last updated 2024-04-26Non Small Cell Lung Cancer

  2. A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

    Active, not recruiting Phase 3 Chia Tai Tianqing (Sino Biopharm) Started 2024Primary completion 2027-01 NCT06561607

    TQB2102 for Injectioncapecitabinepaclitaxel

    Pathologically confirmed locally advanced or metastatic breast cancer with low HER2 expression and unresectable:

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Breast Cancer

  3. A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.

    Active, not recruiting Phase 3 Chia Tai Tianqing (Sino Biopharm) Started 2023Primary completion 2026-12 NCT05987358

    TQB3454 tabletsTQB3454 tablets matching placebo

    …ablets in the Treatment of Advanced Biliary Tract Cancer With Isocitrate Dehydrogenase 1 (IDH1) Mutation.

    IDH1/2 mutationBiliary Carcinoma

  4. FHND9041 Versus Afatinib for Non-small Cell Lung Cancer

    Enrolling by invitation Phase 3 Chia Tai Tianqing (Sino Biopharm) Started 2021Primary completion 2025-03 NCT06759857

    FHND9041afatinib FDA EU

    …nce of a confirmed EGFR-positive gene mutation sensitive to EGFR-TKI treatment, including exon 19 deletion or L858R mutation.

    EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer

  5. Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid Tumors

    Not yet recruiting Phase 2 Chia Tai Tianqing (Sino Biopharm) Started 2026Primary completion 2028-12 NCT07738679

    TQB3454 tablets

    …ens obtained through surgery or biopsy, and cohort 1 and cohort 2 were confirmed to carry IDH1 R132 gene mutation by molecular testing

    IDH1/2 mutationAdvanced Solid Tumors

  6. Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors

    Recruiting Phase 1/2 Chia Tai Tianqing (Sino Biopharm) Started 2026Primary completion 2028-03 NCT07512583

    TQB2930 injection+TQB2102 for injection

    …ncludes HER2 positive (including Immunohistochemistry (IHC) 3+, IHC 2+and Fish positive), HER2 low expression (including IHC 1+ IHC 2+and Fish negative, HC 0 but with HER2 expression);

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Advanced Solid Tumor

  7. A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies

    Recruiting Phase 1 Chia Tai Tianqing (Sino Biopharm) Started 2019Primary completion 2025-12 NCT06550713

    azacitidine

    Clearly indicating the presence of IDH2 gene mutation;

    IDH1/2 mutationStatus may be outdated, last updated 2024-08-13Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)